Gyre Therapeutics, Inc. GYRE Non-Controlling Interests
Non-Controlling Interests at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s non-controlling interests.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s non-controlling interests?
- Gyre Therapeutics, Inc. (GYRE) reported non-controlling interests of $35.68M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s non-controlling interests changed year-over-year?
- Gyre Therapeutics, Inc.'s non-controlling interests decreased by 1.4% year-over-year, from $36.18M to $35.68M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s non-controlling interests?
- Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s non-controlling interests has grown at a 6.9% compound annual growth rate (CAGR), from $29.7M to $36.25M.
- What does non-controlling interests mean?
- Equity attributable to minority shareholders in subsidiaries not fully owned by the parent — their proportional claim on subsidiary net assets.